Agenda

*topics subject to change prior to date of event

8:00 am WELCOME AND INTRODUCTIONS
Elias Anaissie, M.D., Medical Director CTI Clinical Trial & Consulting; Program Director
8:10 am AML and ALL: STATE OF THE ART IN 2021
Hagop M. Kantarjian, M.D.
8:50 am CML, MDS, MPNs: STATE OF THE ART IN 2021
Hagop M. Kantarjian, M.D.
9:30 am BREAK / VIRTUAL EXHIBITOR HALL
9:45 am UPDATE ON NOVEL THERAPIES FOR HODGKIN LYMPHOMA AND AGGRESSIVE NON-HODGKIN LYMPHOMA
Julie M. Vose, M.D.
10:25 am SEQUENCING THERAPY OPTIONS FOR PATIENTS WITH INDOLENT NHL AND CLL/SLL
Julie M. Vose, M.D.
11:05 am BREAK / VIRTUAL EXHIBITOR HALL
11:20 am MULTIPLE MYELOMA (MM): STATE OF THE ART IN 2021
Vincent Rajkumar, M.D.
12:00 pm AL-AMYLOIDOSIS, WALDENSTROM MACROGLOBULINEMIA (WM): STATE OF THE ART IN 2021
Vincent Rajkumar, M.D.
12:40 pm CLOSING
James Essell, M.D., Medical Director Blood Cancer Center, Program Co-Director
12:45 pm PHARMACYCLICS SPEAKER (non-CME): AN UPDATE ON CLL
Javier Pinilla-Ibarz, M.D.
1:15 pm EXHIBITOR HALL CLOSES